November 26, 2012

Big Pharma Buys Influence in Science Journals

Peter Whoriskey, Washington Post


AP Photo

For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup.

The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best.

Read Full Article ››

TAGGED: Scientific Journals, Publication Bias, Pharmaceutical Industry, Big Pharma

RECOMMENDED ARTICLES

October 24, 2013
Should Science Papers Have a Comments Section?
Francie Diep, PopSci
So, about comments. PubMed, America's federally maintained database of scientific papers, is piloting a system that will allow scientists to leave online comments on papers. PubMed is huge—it includes 22 million citations... more ››
A SIMPLE idea underpins science: “trust, but verify”. Results should always be subject to challenge from experiment. That simple but powerful idea has generated a vast body of knowledge. Since its birth in the 17th... more ››
October 17, 2013
Has Open Access Created Unhealthy System?
Kristian Secher, SciNordic
Troubles within academic publishing were recently brought to attention by a widely-cited exposé on predatory publishers and bad science in open access journals. more ››